Floatz logo

Tirzepatide

Psoriatic Arthritis

JULIO GRANADOS MONTIELprotein_peptidePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Psoriatic Arthritis cohort.

Asset / SponsorPhaseRating
Ixekizumab
NHS Greater Glasgow and Clyde
Phase 3BB
Naltrexone
Brigham and Women's Hospital
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 1CC
Cabozantinib
National Cancer Institute (NCI)
Phase 1CC
Nivolumab
National Cancer Institute (NCI)
Phase 1CC
Metformin
University of Alexandria
N/AD
Guselkumab
University of California, San Diego
UnknownD

Same molecule, other indications

Tirzepatide is also rated in:

type 1 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →
diastolic heart failureActive
BBB
Indicative · Phase 4
74 / 100
View asset →
metabolic diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →